ArticleMedicine2026
Association of early lactate with 365-day all-cause mortality in critically ill patients with acute ischemic stroke: A retrospective cohort study using MIMIC-IV.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Lactate may integrate tissue hypoperfusion, adrenergic stress, impaired hepatic clearance, and metabolic responses to cerebral ischemia. Although not stroke-specific, early elevation may identify critically ill patients with concurrent neurological injury and extracerebral organ dysfunction. We evaluated the association between early lactate and all-cause mortality in critically ill patients with a hospitalization-level acute ischemic stroke (AIS) diagnosis. This retrospective cohort study used Medical Information Mart for Intensive Care IV version 3.1 (2008-2022). Adults with an AIS code in any diagnosis position were screened. The earliest lactate recorded during the index intensive care unit stay was used. The primary outcome was 365-day all-cause mortality. Adjusted Cox regression assessed time-to-event associations, and logistic regression evaluated fixed-horizon outcomes. Models were adjusted for demographics, comorbidity burden, neurological and global illness severity, organ dysfunction, hemodynamic and laboratory variables, and liver disease. Patients with and without lactate measurements were compared; calibration, restricted cubic splines, Kaplan-Meier curves, subgroup, decision curve, and sensitivity analyses were also performed. Among 2001 eligible patients, 859 had an early lactate measurement and 1142 did not; measured patients had greater illness severity and more frequent invasive ventilation. During 365 days, 286 patients (33.3%) died. Each 1 mmol/L lactate increase was associated with higher mortality (adjusted hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.07-1.22; P < .001). Versus Q1, adjusted HRs were 1.74 (95% CI, 1.22-2.50) for Q3 and 2.00 (95% CI, 1.37-2.92) for Q4. Adding lactate increased the 5-fold cross-validated area under the curve from 0.744 to 0.755 and reduced the Brier score from 0.187 to 0.182, with calibration slopes of 0.87 and 0.86. Early lactate was associated with short- and long-term all-cause mortality in critically ill patients with a hospitalization-level AIS diagnosis. Selection into lactate testing was substantial, the incremental predictive gain was small, and external validation is required. Lactate should be interpreted as a complementary marker of systemic and neurological stress rather than a stand-alone predictor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.